AU2003249604B2 - A2B adenosine receptor antagonists - Google Patents
A2B adenosine receptor antagonists Download PDFInfo
- Publication number
- AU2003249604B2 AU2003249604B2 AU2003249604A AU2003249604A AU2003249604B2 AU 2003249604 B2 AU2003249604 B2 AU 2003249604B2 AU 2003249604 A AU2003249604 A AU 2003249604A AU 2003249604 A AU2003249604 A AU 2003249604A AU 2003249604 B2 AU2003249604 B2 AU 2003249604B2
- Authority
- AU
- Australia
- Prior art keywords
- dione
- trihydropurine
- formula
- compound
- dipropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011224104A AU2011224104B2 (en) | 2003-05-06 | 2011-09-16 | A2B adenosine receptor antagonists |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011224104A Division AU2011224104B2 (en) | 2003-05-06 | 2011-09-16 | A2B adenosine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003249604A1 AU2003249604A1 (en) | 2005-01-21 |
| AU2003249604B2 true AU2003249604B2 (en) | 2011-06-30 |
Family
ID=33488737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003249604A Ceased AU2003249604B2 (en) | 2003-05-06 | 2003-05-06 | A2B adenosine receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1622908B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006515316A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100590125C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE403656T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003249604B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2524778C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1108457T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60322748D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1622908T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2311759T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05011860A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ543416A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1622908E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1622908T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004106337A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| JP5460690B2 (ja) * | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| BRPI1009398A2 (pt) * | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2616470B1 (en) * | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| MX370372B (es) | 2013-03-15 | 2019-12-11 | Hydra Biosciences Inc | Xantinas sustituidas y metodos de uso de las mismas. |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
| EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| JP7849948B2 (ja) * | 2018-03-05 | 2026-04-22 | テオン セラピューティクス,インク. | アデノシン受容体アンタゴニストおよびその使用 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| CN118459463B (zh) * | 2024-07-10 | 2024-09-06 | 山东中医药大学附属医院 | 一种化合物及其制备方法和治疗2型糖尿病的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879296A (en) * | 1985-04-27 | 1989-11-07 | Burroughs Wellcome Co. | Xanthine derivatives |
| WO2000073307A2 (en) * | 1999-06-01 | 2000-12-07 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4878296A (en) * | 1988-04-22 | 1989-11-07 | The United States Of America As Represented By The Secretary Of The Navy | Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| DE69812070T2 (de) * | 1998-04-24 | 2003-12-11 | K.U. Leuven Research & Development, Leuven | Immununterdrückende Effekte von 8 substituierten Xanthinderivaten |
| ATE307132T1 (de) * | 2001-06-29 | 2005-11-15 | Cv Therapeutics Inc | Purin derivate als a2b adenosin rezeptor antagonisten |
| AU2002359365B2 (en) * | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| MXPA03008967A (es) * | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
-
2003
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en not_active Ceased
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 EP EP03817096A patent/EP1622908B1/en not_active Expired - Lifetime
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879296A (en) * | 1985-04-27 | 1989-11-07 | Burroughs Wellcome Co. | Xanthine derivatives |
| WO2000073307A2 (en) * | 1999-06-01 | 2000-12-07 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1622908T3 (da) | 2008-11-17 |
| CA2524778C (en) | 2013-01-29 |
| SI1622908T1 (sl) | 2008-12-31 |
| AU2003249604A1 (en) | 2005-01-21 |
| NZ543416A (en) | 2009-01-31 |
| PT1622908E (pt) | 2008-11-14 |
| CY1108457T1 (el) | 2014-04-09 |
| CN100590125C (zh) | 2010-02-17 |
| ATE403656T1 (de) | 2008-08-15 |
| HK1092137A1 (en) | 2007-02-02 |
| CN1771250A (zh) | 2006-05-10 |
| WO2004106337A1 (en) | 2004-12-09 |
| DE60322748D1 (de) | 2008-09-18 |
| MXPA05011860A (es) | 2006-02-17 |
| JP2006515316A (ja) | 2006-05-25 |
| ES2311759T3 (es) | 2009-02-16 |
| EP1622908A1 (en) | 2006-02-08 |
| CA2524778A1 (en) | 2004-12-09 |
| EP1622908B1 (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6977300B2 (en) | A2B adenosine receptor antagonists | |
| US8324224B2 (en) | A2B adenosine receptor antagonists | |
| EP1444233B1 (en) | A2b adenosine receptor antagonists | |
| AU2002359365A1 (en) | A2B adenosine receptor antagonists | |
| CA2524778C (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| US7304070B2 (en) | A2B adenosine receptor antagonists | |
| AU2011224104B2 (en) | A2B adenosine receptor antagonists | |
| RU2318825C2 (ru) | Производные ксантина в качестве антагонистов a2b аденозинового рецептора | |
| HK1092137B (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| ES2368998T3 (es) | Antagonistas del receptor de adenosina a2b. | |
| HK1071127B (en) | A2b adenosine receptor antagonists | |
| NZ573577A (en) | Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea | |
| KR20060055453A (ko) | A2b 아데노신 수용체 길항제로서의 크산틴 유도체 | |
| AU2011202523B2 (en) | A2B adenosine receptor antagonists | |
| ZA200508262B (en) | Xanthine derivatives as A2B adenosine receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ A2B ADENOSINE RECEPTOR ANTAGONISTS |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: GILEAD SCIENCES, INC. Free format text: FORMER OWNER WAS: GILEAD PALO ALTO, INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |